Loading...
Header Logo
Keywords
Last Name
Institution

WEI WANG

TitleAssistant Professor
InstitutionMD Anderson
DepartmentHematopathology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Wang W, Routbort MJ, Loghavi S, Tang Z, Medeiros LJ, Wang SA. Characterization of chronic myelomonocytic leukemia with TP53 mutations. Leuk Res. 2018 07; 70:97-99. PMID: 29908419.
      View in: PubMed
    2. Wang W, Tang G, Cortes JE, Liu H, Ai D, Yin CC, Li S, Khoury JD, Bueso-Ramos C, Medeiros LJ, Hu S. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015 Apr 08; 8:32. PMID: 25888368.
      View in: PubMed
    3. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leukemia and Lymphoma. 1-5.
    4. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. Blood Cancer Journal. 6.
    5. Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms. Molecular Cytogenetics. 9.
    6. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer. Oncotarget. 6:36894-36902.
    7. Subcutaneous panniculitis-like T cell lymphoma with mesenteric involvement. Journal of Hematopathology. 6:155-159.
    8. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia.
    9. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 127:2742-2750.
    10. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia. Journal of Hematology and Oncology. 8.
    11. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 126:1699-1706.
    12. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer Journal. 6.
    13. Double-hit follicular lymphoma with MYC and BCL2 translocations. Human Pathology. 58:72-77.
    14. Cytogenetic evolution associated with disease progression in Hematopoietic neoplasms with t(8;22)(p11;q11)/BCR-FQFR1 rearrangement. JNCCN Journal of the National Comprehensive Cancer Network. 14:708-711.
    15. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Annals of Hematology. 1-4.
    16. Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. Blood. 128:877-880.
    17. T-lymphoid or T/myeloid blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. International Journal of Laboratory Hematology.
    18. Refractory hairy cell leukemia-variant. American Journal of Hematology.
    WANG's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description